International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250microg or 500microg or Open-label Betaseron/Betaferon 250microg and (Phase B): Open-label Betaseron/Betaferon 500microg [EXTENSION OF 700004820]

Trial Profile

International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250microg or 500microg or Open-label Betaseron/Betaferon 250microg and (Phase B): Open-label Betaseron/Betaferon 500microg [EXTENSION OF 700004820]

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms BEYOND Follow-up
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top